Literature DB >> 17043636

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.

J Clark1, S Merson, S Jhavar, P Flohr, S Edwards, C S Foster, R Eeles, F L Martin, D H Phillips, M Crundwell, T Christmas, A Thompson, C Fisher, G Kovacs, C S Cooper.   

Abstract

TMPRSS2-ERG gene fusions have recently been reported to be present in a high proportion of human prostate cancers. In the current study, we show that great diversity exists in the precise structure of TMPRSS2-ERG hybrid transcripts found in human prostates. Fourteen distinct hybrid transcripts are characterized, each containing different combinations of sequences from the TMPRSS2 and ERG genes. The transcripts include two that are predicted to encode a normal full-length ERG protein, six that encode N-terminal truncated ERG proteins and one that encodes a TMPRSS2-ERG fusion protein. Interestingly, distinct patterns of hybrid transcripts were found in samples taken from separate regions of individual cancer-containing prostates, suggesting that TMPRSS2-ERG gene fusions may be arising independently in different regions of a single prostate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043636     DOI: 10.1038/sj.onc.1210070

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  112 in total

1.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

Review 4.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

5.  Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.

Authors:  Longjiang Shao; Nermin Kahraman; Ge Yan; Jianghua Wang; Bulent Ozpolat; Michael Ittmann
Journal:  Prostate       Date:  2019-10-15       Impact factor: 4.104

6.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 7.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 8.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

9.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

10.  Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Leni Kauko; Pauliina Helo; Henna Kekki; Angel M Cronin; Andrew J Vickers; Martti Nurmi; Kalle Alanen; Anders Bjartell; Kim Pettersson
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.